title: Ð£ÑÐ¾Ð²ÐµÐ½Ñ Ð³Ð»Ð¾Ð±Ð°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð³ÐµÐ½Ð¾Ð¼Ð½Ð¾Ð¹ ÐÐÐ ÐºÐ»ÐµÑÐ¾Ðº Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð¿ÑÐ¸ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: The level of global methylation of genomic DNA in peripheral blood cells in patients with Parkinsons disease
Creators: name: ÐÐµÐ¼Ð¸Ð´Ð¾Ð²Ð°, ÐÐ²Ð³ÐµÐ½Ð¸Ñ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2024
Subjects: Ð±Ð¾Ð»ÐµÐ·Ð½Ñ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°
Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ ÐÐÐ
Ð°Ð»ÑÑÐ°-ÑÐ¸Ð½ÑÐºÐ»ÐµÐ¸Ð½
SNCA
CD45+ ÐºÐ»ÐµÑÐºÐ¸ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸
Parkinsons disease
DNA methylation
a-synuclein
CD45+ peripheral blood cells

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¸Ð·ÑÑÐµÐ½Ð¸Ñ ÑÑÐµÐ¿ÐµÐ½Ð¸ Ð³Ð»Ð¾Ð±Ð°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð³ÐµÐ½Ð¾Ð¼Ð½Ð¾Ð¹ ÐÐÐ Ð¾Ð±ÑÐµÐ¹ Ð»ÐµÐ¹ÐºÐ¾ÑÐ¸ÑÐ°ÑÐ½Ð¾Ð¹ ÑÑÐ°ÐºÑÐ¸Ð¸ Ð¸ CD45+ ÐºÐ»ÐµÑÐ¾Ðº Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸, Ð° ÑÐ°ÐºÐ¶Ðµ Ð¾ÑÐµÐ½ÐºÐµ ÑÑÐ¾Ð²Ð½Ñ Ð°Ð»ÑÑÐ°-ÑÐ¸Ð½ÑÐºÐ»ÐµÐ¸Ð½Ð° Ð² CD45+ ÐºÐ»ÐµÑÐºÐ°Ñ ÐºÑÐ¾Ð²Ð¸ ÐºÐ°Ðº Ð¿Ð¾ÑÐµÐ½ÑÐ¸Ð°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð±Ð¸Ð¾Ð¼Ð°ÑÐºÐµÑÐ° ÐÐ. ÐÐ»Ñ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ð±ÑÐ»Ð¸ ÑÐ¾Ð±ÑÐ°Ð½Ñ Ð¾Ð±ÑÐ°Ð·ÑÑ ÐºÑÐ¾Ð²Ð¸ Ð»Ð¸Ñ ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½Ð¾Ð¹ Ð³ÑÑÐ¿Ð¿Ñ Ð¸ Ð³ÑÑÐ¿Ð¿Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ, Ð½Ðµ Ð¿ÑÐ¸Ð½Ð¸Ð¼Ð°ÑÑÐ¸Ñ Ð-ÐÐÐ¤Ð-ÑÐ¾Ð´ÐµÑÐ¶Ð°ÑÐ¸Ðµ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÑ, Ð¿Ð¾ÑÐºÐ¾Ð»ÑÐºÑ Ð¿Ð¾ÑÐ»ÐµÐ´Ð½Ð¸Ðµ Ð¼Ð¾Ð³ÑÑ Ð²Ð»Ð¸ÑÑÑ Ð½Ð° ÑÑÐ¾Ð²ÐµÐ½Ñ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð³ÐµÐ½Ð¾Ð¼Ð½Ð¾Ð¹ ÐÐÐ. CD45+ ÐºÐ»ÐµÑÐºÐ¸ Ð²ÑÐ´ÐµÐ»ÑÐ»Ð¸ Ð¸Ð· Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ ÑÐµÐ½ÑÑÐ¸ÑÑÐ³Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸ÐµÐ¼ Ð² Ð³ÑÐ°Ð´Ð¸ÐµÐ½ÑÐµ Ð¿Ð»Ð¾ÑÐ½Ð¾ÑÑÐ¸ ÑÐ°ÑÑÐ²Ð¾ÑÐ° ÑÐ¸ÐºÐ¾Ð»Ð»Ð° Ñ Ð¿Ð¾ÑÐ»ÐµÐ´ÑÑÑÐµÐ¹ Ð¼Ð°Ð³Ð½Ð¸ÑÐ½Ð¾Ð¹ ÑÐµÐ¿Ð°ÑÐ°ÑÐ¸ÐµÐ¹. ÐÑÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ ÐÐÐ Ð¾ÑÑÑÐµÑÑÐ²Ð»ÑÐ»Ð¾ÑÑ Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ ÑÐµÐ½Ð¾Ð»-ÑÐ»Ð¾ÑÐ¾ÑÐ¾ÑÐ¼Ð½Ð¾Ð¹ ÑÐºÑÑÑÐ°ÐºÑÐ¸Ð¸ Ð¸Ð· Ð¾Ð±ÑÐ°Ð·ÑÐ¾Ð² ÑÐµÐ»ÑÐ½Ð¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð¸ CD45+ ÐºÐ»ÐµÑÐ¾Ðº. ÐÑÐµÐ½ÐºÐ° ÑÑÐ¾Ð²Ð½Ñ Ð±ÐµÐ»ÐºÐ° Ð°Ð»ÑÑÐ°-ÑÐ¸Ð½ÑÐºÐ»ÐµÐ¸Ð½Ð° Ð² Ð»Ð¸Ð·Ð°ÑÐ°Ñ CD45+ ÐºÐ»ÐµÑÐ¾Ðº Ð¸ ÑÑÐ¾Ð²Ð½Ñ Ð³Ð»Ð¾Ð±Ð°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ ÐÐÐ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð¿ÑÐ¾Ð²Ð¾Ð´Ð¸Ð»Ð¸ÑÑ Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐµÑÐ¼ÐµÐ½ÑÐ½Ð¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð°. Ð ÑÐ¾Ð´Ðµ Ð´Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ð±ÑÐ»Ð¾ ÑÑÑÐ°Ð½Ð¾Ð²Ð»ÐµÐ½Ð¾, ÑÑÐ¾ ÐÐ ÑÐ°ÑÐ°ÐºÑÐµÑÐ¸Ð·ÑÐµÑÑÑ ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸ÐµÐ¼ ÑÑÐ¾Ð²Ð½Ñ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð³ÐµÐ½Ð¾Ð¼Ð½Ð¾Ð¹ ÐÐÐ Ð¾Ð±ÑÐµÐ¹ ÑÑÐ°ÐºÑÐ¸Ð¸ Ð»ÐµÐ¹ÐºÐ¾ÑÐ¸ÑÐ¾Ð² Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð². ÐÐ¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ ÐÐ ÑÐ¾Ð¿ÑÐ¾Ð²Ð¾Ð¶Ð´Ð°ÐµÑÑÑ Ð¿Ð¾Ð²ÑÑÐµÐ½Ð¸ÐµÐ¼ ÑÑÐ¾Ð²Ð½Ñ Ð°Ð»ÑÑÐ°-ÑÐ¸Ð½ÑÐºÐ»ÐµÐ¸Ð½Ð° Ð² CD45+ ÐºÐ»ÐµÑÐºÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð².Â  Ð£ÑÑÐ°Ð½Ð¾Ð²Ð»ÐµÐ½Ð¾, ÑÑÐ¾ Ñ Ð²Ð¾Ð·ÑÐ°ÑÑÐ¾Ð¼ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ ÑÐ²ÐµÐ»Ð¸ÑÐ¸Ð²Ð°ÐµÑÑÑ ÑÑÐ¾Ð²ÐµÐ½Ñ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð³ÐµÐ½Ð¾Ð¼Ð½Ð¾Ð¹ ÐÐÐ Ð² CD45+ ÐºÐ»ÐµÑÐºÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸. Ð ÑÐ¾ Ð¶Ðµ Ð²ÑÐµÐ¼Ñ Ð½Ðµ Ð±ÑÐ»Ð¾ Ð¾Ð±Ð½Ð°ÑÑÐ¶ÐµÐ½Ð¾ ÐºÐ¾ÑÑÐµÐ»ÑÑÐ¸Ð¸ ÑÑÐ¾Ð²Ð½Ñ Ð°Ð»ÑÑÐ°-ÑÐ¸Ð½ÑÐºÐ»ÐµÐ¸Ð½Ð° Ñ ÑÑÐ¾Ð²Ð½ÐµÐ¼ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð² Ð³ÑÑÐ¿Ð¿Ðµ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ Ð¸ ÑÑÐµÐ´Ð¸ Ð»Ð¸Ñ ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½Ð¾Ð¹ Ð³ÑÑÐ¿Ð¿Ñ. ÐÐ¾Ð»ÑÑÐµÐ½Ð½ÑÐµ Ð´Ð°Ð½Ð½ÑÐµ ÑÐ²Ð¸Ð´ÐµÑÐµÐ»ÑÑÑÐ²ÑÑÑ Ð¾ ÑÐ¾Ð¼, ÑÑÐ¾ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ Ð³ÐµÐ½Ð¾Ð¼Ð½Ð¾Ð¹ ÐÐÐ Ð² ÐÐ¤Ð, Ð° ÑÐ°ÐºÐ¶Ðµ Ð¿Ð¾Ð²ÑÑÐµÐ½Ð¸Ðµ ÑÑÐ¾Ð²Ð½Ñ SNCA Ð² CD45+ ÐºÐ»ÐµÑÐºÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð¼Ð¾Ð³ÑÑ Ð²ÑÑÑÑÐ¿Ð°ÑÑ Ð² ÐºÐ°ÑÐµÑÑÐ²Ðµ Ð¿Ð¾ÑÐµÐ½ÑÐ¸Ð°Ð»ÑÐ½ÑÑ Ð¼Ð°ÑÐºÐµÑÐ¾Ð² ÑÐ°Ð·Ð²Ð¸ÑÐ¸Ñ ÐÐ.
description: In this study, we aim to investigate the level of methylation of genomic DNA within the total leukocyte population and CD45+ cells in peripheral blood samples from patients with PD, as well as assess the level of alpha-synuclein expression in these cells as a potential biomarker for PD. For the study, blood samples were collected from individuals in the control group and a group of patients with PD who did not take L-DOPA-containing medications, as these drugs can affect the methylation of genomic DNA. CD45+ cells were isolated from peripheral blood using a density gradient centrifugation method followed by magnetic separation in a ficoll solution. DNA was extracted from whole blood samples and CD45+ cells using a phenol-chloroform method. The level of alpha-synuclein protein in CD45+ cell lysates and the level of global DNA methylation in peripheral blood were evaluated by enzyme immunoassay. We found that Parkinsons disease is characterized by a decrease in the level of genomic DNA methylation in the total leukocyte fraction of peripheral blood in patients. This may be due to an increase in the level of Î±-synuclein in CD45+ cells in the peripheral blood of PD patients. We also found that there was no correlation between the level of alpha-synuclein and the level of methylation in the group of patients with PD and among the control group. However, there was no correlation between the levels of Î±-synuclein and methylation in PD patients and in the control group. The data suggest that genomic DNA methylation and an increase in Î±-synuclein levels in CD45+ peripheral blood cells may act as potential biomarkers for PD development.